short engagement, selective CDK9 kinase inh.

IV treatment in Ph. I for RR-heme cancers

shortened t1/2 from prior preclin. candidate

J. Med. Chem., Dec. 11, 2020

AstraZeneca, Cambridge, UK / Boston, MA

Structure of AZD4573, a potent and selective inhibitor of CDK9

AstraZeneca selective CDK9 kinase inhibitor

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: